World Journal of Hepatology最新文献_第5页

Unraveling the relationship between histone methylation and nonalcoholic fatty liver disease 揭示组蛋白甲基化与非酒精性脂肪肝之间的关系

IF 2.4

World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.703

Li Xu, Yu-Hong Fan, Xiao-Jing Zhang, Lan Bai

引用次数: 0

Hepatic pseudotumor: A diagnostic challenge 肝假瘤：诊断难题

IF 2.4

World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.667

A. Samanta, Moinak Sen Sarma

引用次数: 0

Multifunctional role of oral bacteria in the progression of non-alcoholic fatty liver disease. 口腔细菌在非酒精性脂肪肝进展过程中的多功能作用。

IF 2.4

World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.688

En-Hua Mei, Chao Yao, Yi-Nan Chen, Shun-Xue Nan, Sheng-Cai Qi

{"title":"Multifunctional role of oral bacteria in the progression of non-alcoholic fatty liver disease.","authors":"En-Hua Mei, Chao Yao, Yi-Nan Chen, Shun-Xue Nan, Sheng-Cai Qi","doi":"10.4254/wjh.v16.i5.688","DOIUrl":"10.4254/wjh.v16.i5.688","url":null,"abstract":"Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver disorders of varying severity, ultimately leading to fibrosis. This spectrum primarily consists of NAFL and non-alcoholic steatohepatitis. The pathogenesis of NAFLD is closely associated with disturbances in the gut microbiota and impairment of the intestinal barrier. Non-gut commensal flora, particularly bacteria, play a pivotal role in the progression of NAFLD. Notably, Porphyromonas gingivalis, a principal bacterium involved in periodontitis, is known to facilitate lipid accumulation, augment immune responses, and induce insulin resistance, thereby exacerbating fibrosis in cases of periodontitis-associated NAFLD. The influence of oral microbiota on NAFLD via the \"oral-gut-liver\" axis is gaining recognition, offering a novel perspective for NAFLD management through microbial imbalance correction. This review endeavors to encapsulate the intricate roles of oral bacteria in NAFLD and explore underlying mechanisms, emphasizing microbial control strategies as a viable therapeutic avenue for NAFLD.","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11135273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141180819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quantifying the natural growth rate of hepatocellular carcinoma: A real-world retrospective study in southwestern China. 量化肝细胞癌的自然生长率：中国西南地区的真实世界回顾性研究。

IF 2.4

World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.800

Li Tu, Hong Xie, Qi Li, Ping-Gui Lei, Pei-Ling Zhao, Fan Yang, Chi Gong, Yuan-Lin Yao, Shi Zhou

{"title":"Quantifying the natural growth rate of hepatocellular carcinoma: A real-world retrospective study in southwestern China.","authors":"Li Tu, Hong Xie, Qi Li, Ping-Gui Lei, Pei-Ling Zhao, Fan Yang, Chi Gong, Yuan-Lin Yao, Shi Zhou","doi":"10.4254/wjh.v16.i5.800","DOIUrl":"10.4254/wjh.v16.i5.800","url":null,"abstract":"Background: In recent years, approximately half of the newly diagnosed cases and mortalities attributed to hepatocellular carcinoma (HCC) have been reported in China. Despite the high incidence of HCC, there remains a paucity of data regarding the natural growth pattern and the determination of optimal surveillance intervals specific to the Chinese population.Aim: To quantify the natural tumor growth pattern of HCC in regional China.Methods: A retrospective analysis was performed on patients from a single institution in Southwest China who had undergone two or more serial dynamic computed tomography or magnetic resonance imaging scans between 2014 and 2020, without having received any anti-cancer therapy. Tumor growth was assessed using tumor volume doubling time (TVDT) and tumor growth rate (TGR), with volumes measured manually by experienced radiologists. Simple univariate linear regression and descriptive analysis were applied to explore associations between growth rates and clinical factors.Results: This study identifies the median TVDT for HCC as 163.4 d, interquartile range (IQR) 72.1 to 302.3 d, with a daily TGR of 0.42% (IQR 0.206%-0.97%). HCC growth patterns reveal that about one-third of tumors grow indolently with TVDT exceeding 270 d, another one-third of tumors exhibit rapid growth with TVDT under 90 d, and the remaining tumors show intermediate growth rates, with TVDT ranging between 3 to 9 months.Conclusion: The identified TGRs support biannual surveillance and follow-up for HCC patients in certain regions of China. Given the observed heterogeneity in HCC growth, further investigation is warranted.","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11135263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141180830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nano-revolution in hepatocellular carcinoma: A multidisciplinary odyssey - Are we there yet? 肝细胞癌的纳米革命：多学科奥德赛--我们成功了吗？

IF 2.4

World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.684

Howard D Lee, Li-Yun Yuan

{"title":"Nano-revolution in hepatocellular carcinoma: A multidisciplinary odyssey - Are we there yet?","authors":"Howard D Lee, Li-Yun Yuan","doi":"10.4254/wjh.v16.i5.684","DOIUrl":"https://doi.org/10.4254/wjh.v16.i5.684","url":null,"abstract":"In this editorial we comment on the review by Zhou et al reviewing the landscape of nanomedicine in the treatment of hepatocellular carcinoma (HCC). We focus on the immense potential of nanotechnology, particularly ligand-receptor mediated nanotherapy, in revolutionizing the treatment landscape of HCC. Despite advancements in multidisciplinary treatment, HCC remains a significant global health challenge. Ligand-mediated nanotherapy offers the opportunity for precise drug delivery to tumor sites, targeting specific receptors overexpressed in HCC cells, thereby enhancing efficacy and minimizing side effects. Overcoming drug resistance and aggressive tumor biology is facilitated by nanomedicine, bypassing traditional hurdles encountered in chemotherapy. Examples include targeting glypican-3, asialoglycoprotein, transferrin receptor or folic acid receptors, capitalizing on their over-expression in tumor cells. The ability for multi-receptor targeting through dual-ligand nanoparticle modification holds the prospect of further enhancement in specificity and efficacy of directed therapy. However, challenges including immune responses, reproducibility in nanoparticle synthesis, and production scalability remain. Future directions involve refining targeting strategies, improving drug release mechanisms, and streamlining production processes to enable personalized and multifunctional nanotherapies. Overall, the integration of nanotherapy in HCC treatment holds immense promise, but continued partnership and effort are needed in offering hope for more effective, precise, and accessible clinical care in the management of HCC.","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141098300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characterization of acute-on-chronic liver diseases: A multicenter prospective cohort study 急性慢性肝病的特征：多中心前瞻性队列研究

IF 2.4

World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.809

Yuan-Yao Zhang, Sen Luo, Hai Li, Shu-Ning Sun, Xian-Bo Wang, Xin Zheng, Yan Huang, Bei-Ling Li, Yan-Hang Gao, Zhiping Qian, Feng Liu, Xiao-Bo Lu, Jun-Ping Liu, Hao-Tang Ren, Yu-Bao Zheng, Hua-Dong Yan, Guo-Hong Deng, Liang Qiao, Yan Zhang, W. Gu, Xiao-Mei Xiang, Yi Zhou, Yi-Xin Hou, Qun Zhang, Yan Xiong, Cong-cong Zou, Jun Chen, Ze-bing Huang, Xiuhua Jiang, Ting-Ting Qi, Yuan-Yuan Chen, Na Gao, Chun-Yan Liu, Wei Yuan, Xue Mei, Jing Li, Tao Li, Rong-Jiong Zheng, Xin-Yi Zhou, Jun Zhao, Zhong-Ji Meng

{"title":"Characterization of acute-on-chronic liver diseases: A multicenter prospective cohort study","authors":"Yuan-Yao Zhang, Sen Luo, Hai Li, Shu-Ning Sun, Xian-Bo Wang, Xin Zheng, Yan Huang, Bei-Ling Li, Yan-Hang Gao, Zhiping Qian, Feng Liu, Xiao-Bo Lu, Jun-Ping Liu, Hao-Tang Ren, Yu-Bao Zheng, Hua-Dong Yan, Guo-Hong Deng, Liang Qiao, Yan Zhang, W. Gu, Xiao-Mei Xiang, Yi Zhou, Yi-Xin Hou, Qun Zhang, Yan Xiong, Cong-cong Zou, Jun Chen, Ze-bing Huang, Xiuhua Jiang, Ting-Ting Qi, Yuan-Yuan Chen, Na Gao, Chun-Yan Liu, Wei Yuan, Xue Mei, Jing Li, Tao Li, Rong-Jiong Zheng, Xin-Yi Zhou, Jun Zhao, Zhong-Ji Meng","doi":"10.4254/wjh.v16.i5.809","DOIUrl":"https://doi.org/10.4254/wjh.v16.i5.809","url":null,"abstract":"BACKGROUND\u0000 Acute-on-chronic liver disease (AoCLD) accounts for the majority of patients hospitalized in the Department of Hepatology or Infectious Diseases.\u0000 AIM\u0000 To explore the characterization of AoCLD to provide theoretical guidance for the accurate diagnosis and prognosis of AoCLD.\u0000 METHODS\u0000 Patients with AoCLD from the Chinese Acute-on-Chronic Liver Failure (ACLF) study cohort were included in this study. The clinical characteristics and outcomes, and the 90-d survival rate associated with each clinical type of AoCLD were analyzed, using the Kaplan-Meier method and the log-rank test.\u0000 RESULTS\u0000 A total of 3375 patients with AoCLD were enrolled, including 1679 (49.7%) patients with liver cirrhosis acute decompensation (LC-AD), 850 (25.2%) patients with ACLF, 577 (17.1%) patients with chronic hepatitis acute exacerbation (CHAE), and 269 (8.0%) patients with liver cirrhosis active phase (LC-A). The most common cause of chronic liver disease (CLD) was HBV infection (71.4%). The most common precipitants of AoCLD was bacterial infection (22.8%). The 90-d mortality rates of each clinical subtype of AoCLD were 43.4% (232/535) for type-C ACLF, 36.0% (36/100) for type-B ACLF, 27.0% (58/215) for type-A ACLF, 9.0% (151/1679) for LC-AD, 3.0% (8/269) for LC-A, and 1.2% (7/577) for CHAE.\u0000 CONCLUSION\u0000 HBV infection is the main cause of CLD, and bacterial infection is the main precipitant of AoCLD. The most common clinical type of AoCLD is LC-AD. Early diagnosis and timely intervention are needed to reduce the mortality of patients with LC-AD or ACLF.","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141098472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Microbiota treatment of functional constipation: Current status and future prospects 功能性便秘的微生物群治疗：现状与前景

IF 2.4

World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.776

Yan Li, Xiao-Han Zhang, Zi-Kai Wang

引用次数: 0

Liver disease in patients with transfusion-dependent β-thalassemia: The emerging role of metabolism dysfunction-associated steatotic liver disease 输血依赖型β地中海贫血患者的肝病：代谢功能障碍相关性脂肪性肝病的新作用

IF 2.4

World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.671

N. Fragkou, E. Vlachaki, Ioannis Goulis, E. Sinakos

{"title":"Liver disease in patients with transfusion-dependent β-thalassemia: The emerging role of metabolism dysfunction-associated steatotic liver disease","authors":"N. Fragkou, E. Vlachaki, Ioannis Goulis, E. Sinakos","doi":"10.4254/wjh.v16.i5.671","DOIUrl":"https://doi.org/10.4254/wjh.v16.i5.671","url":null,"abstract":"In this Editorial, we highlight the possible role that metabolism dysfunction-associated steatotic liver disease (MASLD) may play in the future, regarding liver disease in patients with transfusion-dependent β-thalassemia (TDBT). MASLD is characterized by excessive accumulation of fat in the liver (hepatic steatosis), in the presence of cardiometabolic factors. There is a strong correlation between the occurrence of MASLD and insulin resistance, while its increased prevalence parallels the global epidemic of diabetes mellitus (DM) and obesity. Patients with TDBT need regular transfusions for life to ensure their survival. Through these transfusions, a large amount of iron is accumulated, which causes saturation of transferrin and leads to the circulation of free iron molecules, which cause damage to vital organs (primarily the liver and myocardium). Over the past, the main mechanisms for the development of liver disease in these patients have been the toxic effect of iron on the liver and chronic hepatitis C, for which modern and effective treatments have been found, resulting in successful treatment. Additional advances in the treatment and monitoring of these patients have led to a reduction in deaths, and an increase in their life expectancy. This increased survival makes them vulnerable to the onset of diseases, which until recently were mainly related to the non-thalassemic general population, such as obesity and DM. There is insufficient data in the literature regarding the prevalence of MASLD in this population or on the risk factors for its occurrence. However, it was recently shown by a study of 45 heavily transfused patients with beta-thalassemia (Padeniya et al , BJH), that the presence of steatosis is a factor influencing the value of liver elastography and thus liver fibrosis. These findings suggest that future research in the field of liver disease in patients with TDBT should be focused on the occurrence, the risk factors, and the effect of MASLD on these patients.","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141098134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes of endoscopic submucosal dissection in cirrhotic patients: First American cohort 肝硬化患者内镜黏膜下剥离术的疗效：首个美国队列

IF 2.4

World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.784

Robert L. Pecha, Fares W. Ayoub, Ankur Patel, Abdullah A. Muftah, Michael W Wright, Mai A Khalaf, Mohamed O Othman

{"title":"Outcomes of endoscopic submucosal dissection in cirrhotic patients: First American cohort","authors":"Robert L. Pecha, Fares W. Ayoub, Ankur Patel, Abdullah A. Muftah, Michael W Wright, Mai A Khalaf, Mohamed O Othman","doi":"10.4254/wjh.v16.i5.784","DOIUrl":"https://doi.org/10.4254/wjh.v16.i5.784","url":null,"abstract":"BACKGROUND\u0000 Among patients with cirrhosis and pre-malignant or early malignant mucosal lesions, surgical intervention carries a much higher bleeding risk. When such lesions are discovered, endoscopic submucosal dissection (ESD) may offer curative therapy with lower risks than surgery and improved outcomes compared to traditional endoscopic resection.\u0000 AIM\u0000 To evaluate the outcomes of ESD in patients with cirrhosis.\u0000 METHODS\u0000 Patients with cirrhosis undergoing ESD between July 2015 and August 2022 were retrospectively matched in 1:2 fashion to controls based on lesion location, size, and anticoagulation use. Procedural outcomes were compared between groups.\u0000 RESULTS\u0000 A total of 64 Lesions from 59 patients were included (16 cirrhosis, 43 control). There were no differences in patient or lesion characteristics between groups. En bloc and curative resection was achieved in 84.21%, 78.94% of the cirrhosis group and 88.89%, 68.89% of controls, respectively, with no significant differences. Cirrhotic patients had significantly higher rates of intra-procedural coagulation grasper use for control of bleeding (47.37% vs 20%; P = 0.02). There were otherwise no significant differences in adverse event rates. In the 29 patients with follow up, we found higher rates of recurrence in the cirrhosis group compared to controls (40% vs 5.26%; P = 0.019), however this effect did not persist on multivariable analysis controlling for known confounders.\u0000 CONCLUSION\u0000 ESD may be safe and effective in patients with cirrhosis. Most procedure related outcomes were not significantly different between groups. Intra-procedural bleeding requiring use of the coagulation grasper use was expectedly higher in the cirrhosis group given the known effects of liver disease on hemostasis.","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141098125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetic diversity and occult hepatitis B infection in Africa: A comprehensive review 非洲的遗传多样性与隐性乙型肝炎感染：全面回顾

IF 2.4

World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.843

Michee M Bazie, M. Sanou, F. Djigma, T. Compaoré, D. Obiri-Yeboah, Benoît Kabamba, B. Nagalo, J. Simporé, Rasmata Ouédraogo

{"title":"Genetic diversity and occult hepatitis B infection in Africa: A comprehensive review","authors":"Michee M Bazie, M. Sanou, F. Djigma, T. Compaoré, D. Obiri-Yeboah, Benoît Kabamba, B. Nagalo, J. Simporé, Rasmata Ouédraogo","doi":"10.4254/wjh.v16.i5.843","DOIUrl":"https://doi.org/10.4254/wjh.v16.i5.843","url":null,"abstract":"BACKGROUND\u0000 Occult hepatitis B infection (OBI) is a globally prevalent infection, with its frequency being influenced by the prevalence of hepatitis B virus (HBV) infection in a particular geographic region, including Africa. OBI can be transmitted through blood transfusions and organ transplants and has been linked to the development of hepatocellular carcinoma (HCC). The associated HBV genotype influences the infection.\u0000 AIM\u0000 To highlight the genetic diversity and prevalence of OBI in Africa.\u0000 METHODS\u0000 This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and involved a comprehensive search on PubMed, Google Scholar, Science Direct, and African Journals Online for published studies on the prevalence and genetic diversity of OBI in Africa.\u0000 RESULTS\u0000 The synthesis included 83 articles, revealing that the prevalence of OBI varied between countries and population groups, with the highest prevalence being 90.9% in patients with hepatitis C virus infection and 38% in blood donors, indicating an increased risk of HBV transmission through blood transfusions. Cases of OBI reactivation have been reported following chemotherapy. Genotype D is the predominant, followed by genotypes A and E.\u0000 CONCLUSION\u0000 This review highlights the prevalence of OBI in Africa, which varies across countries and population groups. The study also demonstrates that genotype D is the most prevalent.","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141098139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0